FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131108982> ?p ?o ?g. }

• W3131108982 endingPage "58" @default.
• W3131108982 startingPage "PS9" @default.
• W3131108982 abstract "Abstract Background: Adjuvant endocrine therapy (AET) reduces recurrence and mortality in women with hormone receptor-positive (HR+) breast cancer (BC). Sexual problems are common during AET but are under-reported and under-treated in routine clinical care. Patient reported outcomes (PRO) improve clinician awareness of patient symptoms. We present an analysis of prospectively collected PRO from a clinic-based registry of women with HR+ BC receiving AET with the aim of identifying factors associated with developing or worsening sexual problems. Methods: Women with stage 0-III BC initiating AET were enrolled in a prospective clinic-based registry Mar 2012-Dec 2016. Participants completed PRO surveys at baseline (BL) and 3, 6, 12, 24, 36, 48 and 60 months (mo). Sexual problems were evaluated by the MOS Sexual Problems (MOS-SP) measure (range 0-100; higher scores indicate more sexual problems). Respondents rate severity of problems in 4 domains of sexual function on a 4-point scale (“not a problem”, “a little of a problem”, “somewhat of a problem” and “very much a problem”). We considered participants who responded “somewhat of a problem” or “very much a problem” for ≥1 domain to have a sexual problem at that time point. Based on the empirical rule effect size method, we defined clinically significant developing or worsening sexual problems during AET as an increase in MOS-SP score by ≥8 from BL. Women with MOS-SP score &gt;92 at BL were excluded. Other PRO surveys were the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) scale and NIH PROMIS measures for pain interference, fatigue, depression, anxiety, physical function (PF) and sleep disturbance. We evaluated associations between worsening of PROMIS T-scores in 4-point increments and FACT-ES score in 5-point increments with change in the MOS-SP score by ≥8. Additional covariates were clinical and demographic factors including socioeconomic status (SES). We used neighborhood poverty (NP) rate &gt;15% as a surrogate for low SES based on US census estimates of the % of persons in a zip code below the federal poverty line. We performed logistic regression with generalized estimating equations to account for repeated observations. The final multivariable model was determined with a forward stepwise selection algorithm. Results: Among 300 participants, 195 (65%) were post-menopausal, 252 (84%) white and 30 (10%) black, 134 (45%) on tamoxifen and 166 (55%) on an aromatase inhibitor. Stage distribution was 0: 28 (9%); I: 180 (60%); II-III: 92 (31%). Prior to ET, 132 (44%) had mastectomy, 84 (28%) had chemotherapy and 199 (66%) had radiation (RT). 40 (13%) were of low SES. Median follow-up is 56 mo. 165 (55%) participants reported ≥1 sexual problem during participation. At BL, median MOS-SP score was 8.32 (range 0-92). There was no significant change in mean MOS-SP score from BL to 48 mo (p=0.74). In univariate analyses, worsening scores on all PRO measures were associated with increase in MOS-SP score by ≥8, however on multivariate analysis, only worsening endocrine symptoms (OR 1.34, 95% CI 1.21-1.48, p&lt;0.001) and PF (OR 1.08, 95% CI 0.99-1.18, p=0.06) were retained in the final model. Clinical variables in the final model associated with increase in MOS-SP score by ≥8 were mastectomy (OR 2.00, 95% CI 1.19-3.36, p=0.01) and RT (OR 1.82, 95% CI 1.05-3.16, p=0.03). Women of low SES were less likely to have increase in MOS-SP score by ≥8 (OR 0.49, 95% CI 0.24-0.98, p=0.04). Age, race, stage and type of ET were not associated with developing or worsening sexual problems. Conclusions: Women receiving AET at risk for developing or worsening sexual problems include those with worsening endocrine symptoms and worsening PF plus those who have undergone mastectomy or RT. Routine assessment for sexual problems in this population may reduce under-detection and identify women who can benefit from interventions to improve sexual function. Citation Format: Neha Verma, Amanda L. Blackford, David Lim, Elissa Thorner, Jennifer Lehman, Claire Snyder, Caroline A. Snyder, Vered Stearns, Karen L. Smith. Factors associated with sexual problems during adjuvant endocrine therapy [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-58." @default.
• W3131108982 created "2021-03-01" @default.
• W3131108982 creator A5007572695 @default.
• W3131108982 creator A5012591920 @default.
• W3131108982 creator A5056530735 @default.
• W3131108982 creator A5059257338 @default.
• W3131108982 creator A5063193805 @default.
• W3131108982 creator A5068669130 @default.
• W3131108982 creator A5068872012 @default.
• W3131108982 creator A5072278055 @default.
• W3131108982 creator A5076076101 @default.
• W3131108982 date "2021-02-15" @default.
• W3131108982 modified "2023-09-27" @default.
• W3131108982 title "Abstract PS9-58: Factors associated with sexual problems during adjuvant endocrine therapy" @default.
• W3131108982 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps9-58" @default.
• W3131108982 hasPublicationYear "2021" @default.
• W3131108982 type Work @default.
• W3131108982 sameAs 3131108982 @default.
• W3131108982 citedByCount "0" @default.
• W3131108982 crossrefType "journal-article" @default.
• W3131108982 hasAuthorship W3131108982A5007572695 @default.
• W3131108982 hasAuthorship W3131108982A5012591920 @default.
• W3131108982 hasAuthorship W3131108982A5056530735 @default.
• W3131108982 hasAuthorship W3131108982A5059257338 @default.
• W3131108982 hasAuthorship W3131108982A5063193805 @default.
• W3131108982 hasAuthorship W3131108982A5068669130 @default.
• W3131108982 hasAuthorship W3131108982A5068872012 @default.
• W3131108982 hasAuthorship W3131108982A5072278055 @default.
• W3131108982 hasAuthorship W3131108982A5076076101 @default.
• W3131108982 hasConcept C121608353 @default.
• W3131108982 hasConcept C126322002 @default.
• W3131108982 hasConcept C188816634 @default.
• W3131108982 hasConcept C2775871022 @default.
• W3131108982 hasConcept C29456083 @default.
• W3131108982 hasConcept C46699223 @default.
• W3131108982 hasConcept C71315377 @default.
• W3131108982 hasConcept C71924100 @default.
• W3131108982 hasConceptScore W3131108982C121608353 @default.
• W3131108982 hasConceptScore W3131108982C126322002 @default.
• W3131108982 hasConceptScore W3131108982C188816634 @default.
• W3131108982 hasConceptScore W3131108982C2775871022 @default.
• W3131108982 hasConceptScore W3131108982C29456083 @default.
• W3131108982 hasConceptScore W3131108982C46699223 @default.
• W3131108982 hasConceptScore W3131108982C71315377 @default.
• W3131108982 hasConceptScore W3131108982C71924100 @default.
• W3131108982 hasIssue "4_Supplement" @default.
• W3131108982 hasLocation W31311089821 @default.
• W3131108982 hasOpenAccess W3131108982 @default.
• W3131108982 hasPrimaryLocation W31311089821 @default.
• W3131108982 hasRelatedWork W1508288034 @default.
• W3131108982 hasRelatedWork W2055141553 @default.
• W3131108982 hasRelatedWork W2076993109 @default.
• W3131108982 hasRelatedWork W2159723344 @default.
• W3131108982 hasRelatedWork W2295722933 @default.
• W3131108982 hasRelatedWork W2407093027 @default.
• W3131108982 hasRelatedWork W2411569915 @default.
• W3131108982 hasRelatedWork W2515762743 @default.
• W3131108982 hasRelatedWork W2531350361 @default.
• W3131108982 hasRelatedWork W4283764297 @default.
• W3131108982 hasVolume "81" @default.
• W3131108982 isParatext "false" @default.
• W3131108982 isRetracted "false" @default.
• W3131108982 magId "3131108982" @default.
• W3131108982 workType "article" @default.